A method for determining or validating the therapeutic or diagnostic utility of an antibody or a derivative thereof for an inflammatory and/or cardiovascular disease comprising: (a) subjecting a candidate antibody or derivative thereof to a sample of a coronary thrombus obtained from a patient who had experienced an acute cardiovascular condition and determining the binding of the antibody or derivative thereof to (i) at least one specific cell population, wherein the at least one specific cell population is one or more of T cells, monocytes, eosinophils, neutrophils or granulocytes and/or (ii) a cell specific protein, wherein the protein is specific for the disease, and wherein the expression of the protein is associated with the at least one specific cell population, and; (b) determining the level of specific-binding for the candidate antibody or the derivative thereof by: (iii) calculating the difference mean fluorescent intensity of the candidate antibody or a derivative thereof for coronary thrombi by subtracting the mean fluorescent intensity of a non-specific isotype control antibody in thrombi from the signal given by the candidate antibody in thrombi; (iv) calculating the difference mean fluorescent intensity of the candidate antibody or a derivative thereof for peripheral blood or peripheral thrombus by subtracting the mean fluorescent intensity of the control antibody in peripheral blood or peripheral thrombus from the signal given by the candidate antibody in peripheral blood or peripheral thrombus; and (v) subtracting the difference mean fluorescent intensity calculated in (iv) from the difference mean fluorescent intensity calculated in (iii), wherein the difference mean fluorescent intensity is indicative for the utility of the candidate antibody or derivative thereof as a therapeutic or diagnostic means, wherein the binding is determined by fluorescence activated cytometry. (a) subjecting a candidate antibody or derivative thereof to a sample of a coronary thrombus obtained from a patient who had experienced an acute cardiovascular condition and determining the binding of the antibody or derivative thereof to (i) at least one specific cell population, wherein the at least one specific cell population is one or more of T cells, monocytes, eosinophils, neutrophils or granulocytes and/or (ii) a cell specific protein, wherein the protein is specific for the disease, and wherein the expression of the protein is associated with the at least one specific cell population, and; (i) at least one specific cell population, wherein the at least one specific cell population is one or more of T cells, monocytes, eosinophils, neutrophils or granulocytes and/or (ii) a cell specific protein, wherein the protein is specific for the disease, and wherein the expression of the protein is associated with the at least one specific cell population, and; (b) determining the level of specific-binding for the candidate antibody or the derivative thereof by: (iii) calculating the difference mean fluorescent intensity of the candidate antibody or a derivative thereof for coronary thrombi by subtracting the mean fluorescent intensity of a non-specific isotype control antibody in thrombi from the signal given by the candidate antibody in thrombi; (iv) calculating the difference mean fluorescent intensity of the candidate antibody or a derivative thereof for peripheral blood or peripheral thrombus by subtracting the mean fluorescent intensity of the control antibody in peripheral blood or peripheral thrombus from the signal given by the candidate antibody in peripheral blood or peripheral thrombus; and (v) subtracting the difference mean fluorescent intensity calculated in (iv) from the difference mean fluorescent intensity calculated in (iii), wherein the difference mean fluorescent intensity is indicative for the utility of the candidate antibody or derivative thereof as a therapeutic or diagnostic means, wherein the binding is determined by fluorescence activated cytometry. (iii) calculating the difference mean fluorescent intensity of the candidate antibody or a derivative thereof for coronary thrombi by subtracting the mean fluorescent intensity of a non-specific isotype control antibody in thrombi from the signal given by the candidate antibody in thrombi; (iv) calculating the difference mean fluorescent intensity of the candidate antibody or a derivative thereof for peripheral blood or peripheral thrombus by subtracting the mean fluorescent intensity of the control antibody in peripheral blood or peripheral thrombus from the signal given by the candidate antibody in peripheral blood or peripheral thrombus; and (v) subtracting the difference mean fluorescent intensity calculated in (iv) from the difference mean fluorescent intensity calculated in (iii),